Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Pharmacodynamic Trial of Ezogabine (Retigabine) on Neuronal Excitability in Amyotrophic Lateral Sclerosis

Next Previous
Trial Profile

A Phase 2 Pharmacodynamic Trial of Ezogabine (Retigabine) on Neuronal Excitability in Amyotrophic Lateral Sclerosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Retigabine (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use

Most Recent Events

  • 23 Nov 2020 Primary endpoint (Change in short-interval intracortical inhibition (SICI) measured by transcranial magnetic stimulation (TMS) after treatment with 900 mg/day) has been met, according to results published in the JAMA Neurology
  • 23 Nov 2020 Primary endpoint (Change in short-interval intracortical inhibition (SICI) measured by transcranial magnetic stimulation (TMS) after treatment with 600 mg/day) has not been met, according to results published in the JAMA Neurology
  • 23 Nov 2020 Results published in the JAMA Neurology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top